Corporate Board Profile
Tech Score: 14/100
1 mention(s) identify GARY WILCOX as having software/technology expertise.
| Company | Filing Date | Evidence | Reason |
|---|---|---|---|
| Cocrystal Pharma, Inc. | 2020-04-28 | “Since 2012, Dr. Wilcox has been a director of the Daily Journal Corporation (Nasdaq:DJCO), a publisher of legal newspapers and websites, and a developer of legal case management software.” | He is described as a director of the Daily Journal Corporation, which is identified as 'a developer of legal case management software,' indicating software-adjacent technical involvement. However, the filing does not state that he is a programmer or software engineer, so this is only adjacent technical exposure. |
| Filing Date | Source Excerpt |
|---|---|
| 2015-01-07 | "Dr. Gary Wilcox" ... "Dr. Wilcox is an executive officer and a director." |
| 2015-06-01 | "Dr. Wilcox’s qualifications to serve on our Board include his 30 years of experience as an executive in biotechnology companies, and his technical expertise in drug discovery and development." |
| 2016-06-17 | "Dr. Wilcox’s qualifications to serve on our Board include his 30 years of experience as an executive in biotechnology companies, and his technical expertise in drug discovery and development." |
| 2018-06-25 | "Since 2012, Dr. Wilcox has been a director of the Daily Journal Corporation ... and a developer of legal case management software." |
| 2019-04-30 | "Dr. Wilcox’s qualifications to serve on our Board include his 30 years of experience as an executive in biotechnology companies, his technical expertise in drug discovery and development" |
| 2020-04-28 | “Since 2012, Dr. Wilcox has been a director of the Daily Journal Corporation (Nasdaq:DJCO), a publisher of legal newspapers and websites, and a developer of legal case management software.” |
| 2021-04-26 | "Dr. Wilcox’s qualifications to serve on our Board include his over 30 years of experience as an executive in biotechnology companies, his technical expertise in drug discovery and development" |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-04-25